Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6383-6391

  Demo, Susan D ^a   Kirk, Christopher J ^a   Aujay, Monette A ^a   Buchholz, Tonia J ^a   Dajee, Maya ^a   Ho, Mark N ^a   Jiang, Jing ^a   Laidig, Guy J ^a   Lewis, Evan R ^a   Parlati, Francesco ^a   Shenk, Kevin D ^a   Smyth, Mark S ^a   Sun, Congcong M ^a   Vallone, Marcy K ^a   Woo, Tina M ^a   Molineaux, Christopher J ^a   Bennett, Mark K ^a  

^a Proteolix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CHYMOTRYPSIN; EPOXOMICIN; NPI 0052; PR 171; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD; BRAIN TISSUE; CELL CULTURE; CELL CYCLE ARREST; CELL TRANSFORMATION; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR; TISSUE SPECIFICITY; TUMOR MODEL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CHYMOTRYPSIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34447116376     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4086     Document Type: Article

References (45)

1. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005;6:79-87.
2. Dalton WS. The proteasome. Semin Oncol 2004;31:3-9.
3. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-58.
4. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
5. Kisselev AF, Goldberg AL. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 2005;398:364-78.
6. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4:686-92.
7. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-8.
8. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
9. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75.
10. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
11. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
12. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
13. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-91.
14. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946-51.
15. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
16. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
17. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777-84.
18. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
19. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22:2108-21.
20. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19.
21. Cusack JC, Jr., Liu R, Xia L, et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006;12:6758-64.
22. Macherla VR, Mitchell SS, Manam RR, et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005;48:3684-7.
23. Hanada M, Sugawara K, Kaneta K, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo)199 2;45:1746-52.
24. Sin N, Kim KB, Elofsson M, et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 1999;9:2283-8.
25. Groll M, Kim KB, Kairies N, Huber R, Crews CM. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis of α′, β′-epoxyketone proteasome inhibitors. J Am Chem Soc 2000;122:1237-8.
26. Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′,β′-epoxyketones. Chem Biol 1999;6:811-22.
27. Smyth MS, Laidig GJ. Compounds for enzyme inhibition. US patent application US 2006/0030533 A1.
28. Groettrup M, van den BM, Schwarz K, et al. Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 2001;21:339-58.
29. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006;281:8582-90.
30. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451-6.
31. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
32. Meiners S, Heyken D, Weller A, et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. J Biol Chem 2003;278:21517-25.
33. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
34. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
35. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9:1145-54.
36. Ito H, Kamei K, Iwamoto I, et al. Inhibition of proteasomes induces accumulation, phosphorylation, and recruitment of HSP27 and αB-crystallin to aggresomes. J Biochem Tokyo 2002;131:593-603.
37. 2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841-9.
38. Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63:6174-7.
39. Bush KT, Goldberg AL, Nigam SK. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 1997;272:9086-92.
40. Rogalla T, Ehrnsperger M, Preville X, et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor a by phosphorylation. J Biol Chem 1999;274:18947-56.
41. Stapnes C, Doskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136:814-28.
42. Williamson MJ, Blank JL, Bruzzese FJ, et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A)and bortezomib. Mol Cancer Ther 2006;5:3052-61.
43. Groll M, Huber R, Potts BC. Crystal structures of Salinosporamide A (NPI-0052)and B (NPI-0047)in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006;128:5136-41.
44. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
45. Au JL, Jang SH, Zheng J, et al. Determinants of drug delivery and transport to solid tumors. J Control Release 2001;74:31-46.